#VisualAbstract: Atezolizumab Does Not Improve Outcomes in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma
Click here to read this study in JAMA. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in JAMA. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. We ...
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. ...
Click to read this study in JAMA Network Open.
1. Fewer patients in the hyperfractionation group reported grade 3 or worse late radiation-induced complications compared to the standard fractionation ...
Click to read this study in JAMA Surgery.
Click to read this study in JAMA Network Open.
Click to read this study in JAMA Oncology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.